Dr Brian Hudson
- Lecturer (Molecular Biosciences)
telephone:
+44 0141 330 7160
email:
Brian.Hudson@glasgow.ac.uk
pronouns:
He/him/his
Room 253, Wolfson Link, University of Glasgow, Glasgow G12 8QQ
Research interests
Research groups
Publications
2024
Quon, T., Lin, L.-C., Ganguly, A. , Hudson, B. D. , Tobin, A. B. and Milligan, G. (2024) Biased constitutive signalling of the G protein-coupled receptor GPR35 suppresses gut barrier permeability. Journal of Biological Chemistry, (Accepted for Publication)
2023
Ciba, M., Dibnah, B., Hudson, B. D. and Ulven, E. R. (2023) Development and characterization of potent succinate receptor fluorescent tracers. Journal of Medicinal Chemistry, 66(13), pp. 8951-8974. (doi: 10.1021/acs.jmedchem.3c00552) (PMID:37318348)
Duncan, E., Vita, L., Dibnah, B. and Hudson, B. D. (2023) Metabolite sensing GPCRs controlling interactions between adipose tissue and inflammation. Frontiers in Endocrinology, 14, 1197102. (doi: 10.3389/fendo.2023.1197102) (PMID:37484963) (PMCID:PMC10357040)
2022
Bremner, S. K. , Al Shammari, W. O., Milligan, R. S., Hudson, B. D. , Sutherland, C., Bryant, N. J. and Gould, G. W. (2022) Pleiotropic effects of Syntaxin16 identified by gene editing in cultured adipocytes. Frontiers in Cell and Developmental Biology, 10, 1033501. (doi: 10.3389/fcell.2022.1033501) (PMID:36467416) (PMCID:PMC9716095)
Barki, N. et al. (2022) Chemogenetics defines the roles of short chain fatty acid receptors within the gut-brain axis. eLife, 11, e73777. (doi: 10.7554/eLife.73777) (PMID:35229717) (PMCID:PMC8887895)
Divorty, N., Jenkins, L. , Ganguly, A. , Butcher, A. J., Hudson, B. D. , Schulz, S., Tobin, A. B. , Nicklin, S. A. and Milligan, G. (2022) Agonist-induced phosphorylation of orthologues of the orphan receptor GPR35 functions as an activation sensor. Journal of Biological Chemistry, 298(3), 101655. (doi: 10.1016/j.jbc.2022.101655) (PMID:35101446) (PMCID:PMC8892012)
2021
Scarpa, M. et al. (2021) Biased M1 muscarinic receptor mutant mice show accelerated progression of prion neurodegenerative disease. Proceedings of the National Academy of Sciences of the United States of America, 118(50), e2107389118. (doi: 10.1073/pnas.2107389118) (PMID:34893539) (PMCID:PMC8685681)
Brown, A. J.H. et al. (2021) From structure to clinic: design of a muscarinic M1 receptor agonist with potential to treatment of Alzheimer’s disease. Cell, 184(24), 5886-5901.e22. (doi: 10.1016/j.cell.2021.11.001) (PMID:34822784)
Mahindra, A. et al. (2021) Peptides derived from the SARS-CoV-2 receptor binding motif bind to ACE2 but do not block ACE2-mediated host cell entry or pro-inflammatory cytokine induction. PLoS ONE, 16(11), e0260283. (doi: 10.1371/journal.pone.0260283) (PMID:34793553) (PMCID:PMC8601423)
2020
Rexen Ulven, E. et al. (2020) Structure-activity relationship studies of tetrahydroquinolone free fatty acid receptor 3 modulators. Journal of Medicinal Chemistry, 63(7), pp. 3577-3595. (doi: 10.1021/acs.jmedchem.9b02036) (PMID:32141297) (PMCID:PMC7307922)
2019
Bolognini, D. et al. (2019) Chemogenetics defines receptor-mediated functions of short chain free fatty acids. Nature Chemical Biology, 15(5), pp. 489-498. (doi: 10.1038/s41589-019-0270-1) (PMID:30992568)
Mackenzie, A. E., Quon, T., Lin, L.-C., Hauser, A. S., Jenkins, L. , Inoue, A., Tobin, A. B. , Gloriam, D. E., Hudson, B. D. and Milligan, G. (2019) Receptor selectivity between the G proteins Gα12 and Gα13 is defined by a single leucine-to-isoleucine variation. FASEB Journal, 33(4), pp. 5005-5017. (doi: 10.1096/fj.201801956R) (PMID:30601679) (PMCID:PMC6436656)
2017
Mahmud, Z. A., Jenkins, L. , Ulven, T., Labéguère, F., Gosmini, R., De Vos, S., Hudson, B. D. , Tikhonova, I. G. and Milligan, G. (2017) Three classes of ligands each bind to distinct sites on the orphan G protein-coupled receptor GPR84. Scientific Reports, 7, 17953. (doi: 10.1038/s41598-017-18159-3) (PMID:29263400) (PMCID:PMC5738391)
Sergeev, E. , Hansen, A. H., Bolognini, D., Kawakami, K., Kishi, T., Aoki, J., Ulven, T., Inoue, A., Hudson, B. D. and Milligan, G. (2017) A single extracellular amino acid in Free Fatty Acid Receptor 2 defines antagonist species selectivity and G protein selection bias. Scientific Reports, 7, 13741. (doi: 10.1038/s41598-017-14096-3) (PMID:29061999) (PMCID:PMC5653858)
Milligan, G. , Alvarez-Curto, E. , Hudson, B. D. , Prihandoko, R. and Tobin, A. B. (2017) FFA4/GPR120: pharmacology and therapeutic opportunities. Trends in Pharmacological Sciences, 38(9), pp. 809-821. (doi: 10.1016/j.tips.2017.06.006) (PMID:28734639) (PMCID:PMC5582618)
Watterson, K. R. et al. (2017) Probe-dependent negative allosteric modulators of the long-chain free fatty acid receptor FFA4. Molecular Pharmacology, 91(6), pp. 630-641. (doi: 10.1124/mol.116.107821) (PMID:28385906) (PMCID:PMC5438128)
Houthuijzen, J. M. et al. (2017) Fatty acid 16:4(n-3) stimulates a GPR120-induced signaling cascade in splenic macrophages to promote chemotherapy resistance. FASEB Journal, 31(5), pp. 2195-2209. (doi: 10.1096/fj.201601248R) (PMID:28183801) (PMCID:PMC5388545)
Hansen, A. H., Sergeev, E. , Pandey, S. K., Hudson, B. D. , Christiansen, E., Milligan, G. and Ulven, T. (2017) Development and characterization of a fluorescent tracer for the free fatty acid receptor 2 (FFA2/GPR43). Journal of Medicinal Chemistry, 60(13), pp. 5638-5645. (doi: 10.1021/acs.jmedchem.7b00338) (PMID:28570808)
Milligan, G. , Shimpukade, B., Ulven, T. and Hudson, B. D. (2017) Complex pharmacology of free fatty acid receptors. Chemical Reviews, 117(1), pp. 67-110. (doi: 10.1021/acs.chemrev.6b00056) (PMID:27299848)
2016
Hudson, B. D. (2016) Using biosensors to study free fatty acid receptor pharmacology and function. In: Milligan, G. and Kimura, I. (eds.) Free Fatty Acid Receptors. Series: Handbook of experimental pharmacology (236). Springer, pp. 79-100. ISBN 9783319506920 (doi: 10.1007/164_2016_58)
Azevedo, C. M. G. et al. (2016) Non-acidic free fatty acid receptor 4 agonists with antidiabetic activity. Journal of Medicinal Chemistry, 59(19), pp. 8868-8878. (doi: 10.1021/acs.jmedchem.6b00685)
Hansen, S. V.F. et al. (2016) Discovery of a potent free fatty acid 1 receptor agonist with low lipophilicity, low polar surface area and robust in vivo efficacy. Journal of Medicinal Chemistry, 59, pp. 2841-2846. (doi: 10.1021/acs.jmedchem.5b01962)
Grundmann, M., Tikhonova, I. G., Hudson, B. D. , Smith, N. J., Mohr, K., Ulven, T., Milligan, G. , Kenakin, T. and Kostenis, E. (2016) A molecular mechanism for sequential activation of a G Protein-coupled receptor. Cell Chemical Biology, 23(3), pp. 392-403. (doi: 10.1016/j.chembiol.2016.02.014) (PMID:26991104)
Sergeev, E. , Hansen, A. H., Pandey, S. K., MacKenzie, A. E., Hudson, B. D. , Ulven, T. and Milligan, G. (2016) Non-equivalence of key positively charged residues of the free fatty acid 2 receptor in the recognition and function of agonist versus antagonist ligands. Journal of Biological Chemistry, 291, pp. 303-317. (doi: 10.1074/jbc.M115.687939) (PMID:26518871) (PMCID:PMC4697166)
Christiansen, E., Hudson, B. D. , Hansen, A. H., Milligan, G. and Ulven, T. (2016) Development and characterization of a potent free fatty acid receptor 1 (FFA1) fluorescent tracer. Journal of Medicinal Chemistry, 59(10), pp. 4849-4858. (doi: 10.1021/acs.jmedchem.6b00202) (PMID:27074625)
Prihandoko, R., Alvarez-Curto, E. , Hudson, B. D. , Butcher, A. J., Ulven, T., Miller, A. M., Tobin, A. B. and Milligan, G. (2016) Distinct phosphorylation clusters determines the signalling outcome of the free fatty acid receptor FFA4/GPR120. Molecular Pharmacology, 89(5), pp. 505-520. (doi: 10.1124/mol.115.101949) (PMID:26873857)
2015
Milligan, G. , Alvarez-Curto, E. , Watterson, K.R., Ulven, T. and Hudson, B.D. (2015) Characterizing pharmacological ligands to study the long-chain fatty acid receptors GPR40/FFA1 and GPR120/FFA4. British Journal of Pharmacology, 172(13), pp. 3254-3265. (doi: 10.1111/bph.12879) (PMID:25131623)
Christiansen, E. et al. (2015) Activity of dietary fatty acids on FFA1 and FFA4 and characterisation of pinolenic acid as a dual FFA1/FFA4 agonist with potential effect against metabolic diseases. British Journal of Nutrition, 113(11), pp. 1677-1688. (doi: 10.1017/S000711451500118X) (PMID:25916176)
2014
Hudson, B. D. , Christiansen, E., Murdoch, H., Jenkins, L. , Hansen, A. H., Madsen, O., Ulven, T. and Milligan, G. (2014) Complex pharmacology of novel allosteric free fatty acid 3 receptor ligands. Molecular Pharmacology, 86(2), pp. 200-210. (doi: 10.1124/mol.114.093294)
Hudson, B. D. , Shimpukade, B., Milligan, G. and Ulven, T. (2014) The molecular basis of ligand interaction at free fatty acid receptor 4 (FFA4/GPR120). Journal of Biological Chemistry, 289, pp. 20345-20358. (doi: 10.1074/jbc.M114.561449) (PMID:24860101) (PMCID:PMC4106347)
Butcher, A. J., Hudson, B. D. , Shimpukade, B., Alvarez-Curto, E. , Prihandoko, R., Ulven, T., Milligan, G. and Tobin, A. B. (2014) Concomitant action of structural elements and receptor phosphorylation determine arrestin-3 interaction with the free fatty acid receptor FFA4. Journal of Biological Chemistry, 289, pp. 18451-18465. (doi: 10.1074/jbc.M114.568816) (PMID:24817122) (PMCID:PMC4140278)
Fjaere, E. et al. (2014) Indomethacin treatment prevents high fat diet-induced obesity and insulin resistance but not glucose intolerance in C57BL/6J mice. Journal of Biological Chemistry, 289(23), pp. 16032-16045. (doi: 10.1074/jbc.M113.525220)
Milligan, G. , Ulven, T., Murdoch, H. and Hudson, B. D. (2014) G-protein-coupled receptors for free fatty acids: nutritional and therapeutic targets. British Journal of Nutrition, 111(S1), S3-S7. (doi: 10.1017/S0007114513002249)
Mackenzie, A.E. et al. (2014) The antiallergic mast cell stabilizers lodoxamide and bufrolin as the first high and equipotent agonists of human and rat gpr35. Molecular Pharmacology, 85(1), pp. 91-104. (doi: 10.1124/mol.113.089482)
Watterson, K. R., Hudson, B. D. , Ulven, T. and Milligan, G. (2014) Treatment of type 2 diabetes by free fatty acid receptor agonists. Frontiers in Endocrinology, 5, 137. (doi: 10.3389/fendo.2014.00137) (PMID:25221541) (PMCID:PMC4147718)
2013
Hudson, B.D. , Shimpukade, B., Mackenzie, A.E., Butcher, A.J., Pediani, J.D. , Christiansen, E., Heathcote, H., Tobin, A.B., Ulven, T. and Milligan, G. (2013) The pharmacology of TUG-891, a potent and selective agonist of the free fatty acid receptor 4 (FFA4/GPR120), demonstrates both potential opportunity and possible challenges to therapeutic agonism. Molecular Pharmacology, 84(5), pp. 710-725. (doi: 10.1124/mol.113.087783)
Dranse, H.J., Kelly, M.E.M. and Hudson, B.D. (2013) Drugs or diet? - Developing novel therapeutic strategies targeting the free fatty acid family of GPCRs. British Journal of Pharmacology, 170(4), pp. 696-711. (doi: 10.1111/bph.12327)
Hudson, B. D. , Kulp, K. S. and Loots, G. G. (2013) Prostate cancer invasion and metastasis: insights from mining genomic data. Briefings in Functional Genomics, 12(5), pp. 397-410. (doi: 10.1093/bfgp/elt021)
Hudson, B.D. , Murdoch, H. and Milligan, G. (2013) The effects of species ortholog and SNP variation on receptors for free fatty acids. Molecular Endocrinology, 27(8), pp. 1177-1187. (doi: 10.1210/me.2013-1085)
Hudson, B.D. et al. (2013) Defining the molecular basis for the first potent and selective orthosteric agonists of the FFA2 free fatty acid receptor. Journal of Biological Chemistry, 288(24), pp. 17296-17312. (doi: 10.1074/jbc.M113.455337)
Christiansen, E. et al. (2013) Discovery of TUG-770: a highly potent free fatty acid receptor 1 (FFA1/GPR40) agonist for treatment of type 2 diabetes. ACS Medicinal Chemistry Letters, 4(5), pp. 441-445. (doi: 10.1021/ml4000673)
Christiansen, E. et al. (2013) Discovery of a potent and selective free fatty acid receptor 1 agonist with low lipophilicity and high oral bioavailability. Journal of Medicinal Chemistry, 56(3), pp. 982-992. (doi: 10.1021/jm301470a)
Hudson, B. D. , Ulven, T. and Milligan, G. (2013) The therapeutic potential of allosteric ligands for free fatty acid sensitive GPCRs. Current Topics in Medicinal Chemistry, 13(1), pp. 14-25. (doi: 10.2174/1568026611313010004)
Mackenzie, A. E., Neetoo-Isseljee, Z., Southern, C., Jerman, J., McIver, E. G., Hudson, B. D. , Taylor, D. L. and Milligan, G. (2013) Novel and potent GPR35 agonists aid identification of residues important in ligand interaction. FASEB Journal, 27, 655.1.
2012
Hudson, B. , Christiansen, E., Tikhonova, I.G., Grundmann, M., Kostenis, E., Adams, D.R., Ulven, T. and Milligan, G. (2012) Chemically engineering ligand selectivity at the free fatty acid receptor 2 based on pharmacological variation between species orthologs. FASEB Journal, 26(12), pp. 4951-4965. (doi: 10.1096/fj.12-213314)
Hudson, B.D. , Tikhonova, I.G., Pandey, S.K., Ulven, T. and Milligan, G. (2012) Extracellular ionic locks determine variation in constitutive activity and ligand potency between species orthologs of the free fatty acid receptors FFA2 and FFA3. Journal of Biological Chemistry, 287(49), pp. 41195-41209. (doi: 10.1074/jbc.M112.396259)
Christiansen, E. et al. (2012) Free fatty acid receptor 1 (FFA1/GPR40) agonists: mesylpropoxy appendage lowers lipophilicity and improves ADME properties. Journal of Medicinal Chemistry, 55(14), pp. 6624-6628. (doi: 10.1021/jm3002026)
Shimpukade, B., Hudson, B.D. , Hogaard, C.K., Milligan, G. and Ulven, T. (2012) Discovery of a potent and selective GPR120 agonist. Journal of Medicinal Chemistry, 55(9), pp. 4511-4515. (doi: 10.1021/jm300215x)
Ottenheijm, C. A.C., Voermans, N. C., Hudson, B. D. , Irving, T., Stienen, G. J.M., van Engelen, B. G. and Granzier, H. (2012) Titin-based stiffening of muscle fibers in Ehlers-Danlos Syndrome. Journal of Applied Physiology, 112(7), pp. 1157-1165. (doi: 10.1152/japplphysiol.01166.2011) (PMID:22223454)
Hudson, B. D. and Kelly, M. E.M. (2012) Identification of novel competing β2AR phospho extracellular signal regulated kinase 1/2 signaling pathways in human trabecular meshwork cells. Journal of Ocular Pharmacology and Therapeutics, 28(1), pp. 17-25. (doi: 10.1089/jop.2011.0016)
Terhzaz, S. , Cabrero, P. , Robben, J.H., Radford, J.C., Hudson, B.D. , Milligan, G. , Dow, J.A.T. and Davies, S.A. (2012) Mechanism and function of drosophila capa GPCR: a desiccation stress-responsive receptor with functional homology to human neuromedinU receptor. PLoS ONE, 7(1), e29897. (doi: 10.1371/journal.pone.0029897) (PMID:22253819) (PMCID:PMC3256212)
2011
Smith, N.J. et al. (2011) Extracellular loop 2 of the free fatty acid receptor 2 mediates allosterism of a phenylacetamide ago-allosteric modulator. Molecular Pharmacology, 80(1), pp. 163-173. (doi: 10.1124/mol.110.070789)
Schmidt, J. et al. (2011) Selective orthosteric free fatty acid receptor 2 (FFA2) agonists: identification of the structural and chemical requirements for selective activation of FFA2 versus FFA3. Journal of Biological Chemistry, 286(12), pp. 10628-10640. (doi: 10.1074/jbc.M110.210872)
Hudson, B.D. , Smith, N.J. and Milligan, G. (2011) Experimental challenges to targeting poorly characterized GPCRs: uncovering the therapeutic potential for free fatty acid receptors. In: Neubig, R.R. (ed.) Pharmacology of G Protein Coupled Receptors. Series: Advances in Pharmacology (62). Elsevier Academic Press: Amsterdam, The Netherlands, pp. 175-218. ISBN 9780123859525 (doi: 10.1016/B978-0-12-385952-5.00006-3)
2010
Jenkins, L. , Brea, J., Smith, N.J., Hudson, B.D. , Reilly, G., Bryant, N.J., Castro, M., Loza, M.I. and Milligan, G. (2010) Identification of novel species-selective agonists of the G-protein-coupled receptor GPR35 that promote recruitment of β-arrestin-2 and activate Gα13. Biochemical Journal, 432(3), pp. 451-459. (doi: 10.1042/BJ20101287)
Articles
Quon, T., Lin, L.-C., Ganguly, A. , Hudson, B. D. , Tobin, A. B. and Milligan, G. (2024) Biased constitutive signalling of the G protein-coupled receptor GPR35 suppresses gut barrier permeability. Journal of Biological Chemistry, (Accepted for Publication)
Ciba, M., Dibnah, B., Hudson, B. D. and Ulven, E. R. (2023) Development and characterization of potent succinate receptor fluorescent tracers. Journal of Medicinal Chemistry, 66(13), pp. 8951-8974. (doi: 10.1021/acs.jmedchem.3c00552) (PMID:37318348)
Duncan, E., Vita, L., Dibnah, B. and Hudson, B. D. (2023) Metabolite sensing GPCRs controlling interactions between adipose tissue and inflammation. Frontiers in Endocrinology, 14, 1197102. (doi: 10.3389/fendo.2023.1197102) (PMID:37484963) (PMCID:PMC10357040)
Bremner, S. K. , Al Shammari, W. O., Milligan, R. S., Hudson, B. D. , Sutherland, C., Bryant, N. J. and Gould, G. W. (2022) Pleiotropic effects of Syntaxin16 identified by gene editing in cultured adipocytes. Frontiers in Cell and Developmental Biology, 10, 1033501. (doi: 10.3389/fcell.2022.1033501) (PMID:36467416) (PMCID:PMC9716095)
Barki, N. et al. (2022) Chemogenetics defines the roles of short chain fatty acid receptors within the gut-brain axis. eLife, 11, e73777. (doi: 10.7554/eLife.73777) (PMID:35229717) (PMCID:PMC8887895)
Divorty, N., Jenkins, L. , Ganguly, A. , Butcher, A. J., Hudson, B. D. , Schulz, S., Tobin, A. B. , Nicklin, S. A. and Milligan, G. (2022) Agonist-induced phosphorylation of orthologues of the orphan receptor GPR35 functions as an activation sensor. Journal of Biological Chemistry, 298(3), 101655. (doi: 10.1016/j.jbc.2022.101655) (PMID:35101446) (PMCID:PMC8892012)
Scarpa, M. et al. (2021) Biased M1 muscarinic receptor mutant mice show accelerated progression of prion neurodegenerative disease. Proceedings of the National Academy of Sciences of the United States of America, 118(50), e2107389118. (doi: 10.1073/pnas.2107389118) (PMID:34893539) (PMCID:PMC8685681)
Brown, A. J.H. et al. (2021) From structure to clinic: design of a muscarinic M1 receptor agonist with potential to treatment of Alzheimer’s disease. Cell, 184(24), 5886-5901.e22. (doi: 10.1016/j.cell.2021.11.001) (PMID:34822784)
Mahindra, A. et al. (2021) Peptides derived from the SARS-CoV-2 receptor binding motif bind to ACE2 but do not block ACE2-mediated host cell entry or pro-inflammatory cytokine induction. PLoS ONE, 16(11), e0260283. (doi: 10.1371/journal.pone.0260283) (PMID:34793553) (PMCID:PMC8601423)
Rexen Ulven, E. et al. (2020) Structure-activity relationship studies of tetrahydroquinolone free fatty acid receptor 3 modulators. Journal of Medicinal Chemistry, 63(7), pp. 3577-3595. (doi: 10.1021/acs.jmedchem.9b02036) (PMID:32141297) (PMCID:PMC7307922)
Bolognini, D. et al. (2019) Chemogenetics defines receptor-mediated functions of short chain free fatty acids. Nature Chemical Biology, 15(5), pp. 489-498. (doi: 10.1038/s41589-019-0270-1) (PMID:30992568)
Mackenzie, A. E., Quon, T., Lin, L.-C., Hauser, A. S., Jenkins, L. , Inoue, A., Tobin, A. B. , Gloriam, D. E., Hudson, B. D. and Milligan, G. (2019) Receptor selectivity between the G proteins Gα12 and Gα13 is defined by a single leucine-to-isoleucine variation. FASEB Journal, 33(4), pp. 5005-5017. (doi: 10.1096/fj.201801956R) (PMID:30601679) (PMCID:PMC6436656)
Mahmud, Z. A., Jenkins, L. , Ulven, T., Labéguère, F., Gosmini, R., De Vos, S., Hudson, B. D. , Tikhonova, I. G. and Milligan, G. (2017) Three classes of ligands each bind to distinct sites on the orphan G protein-coupled receptor GPR84. Scientific Reports, 7, 17953. (doi: 10.1038/s41598-017-18159-3) (PMID:29263400) (PMCID:PMC5738391)
Sergeev, E. , Hansen, A. H., Bolognini, D., Kawakami, K., Kishi, T., Aoki, J., Ulven, T., Inoue, A., Hudson, B. D. and Milligan, G. (2017) A single extracellular amino acid in Free Fatty Acid Receptor 2 defines antagonist species selectivity and G protein selection bias. Scientific Reports, 7, 13741. (doi: 10.1038/s41598-017-14096-3) (PMID:29061999) (PMCID:PMC5653858)
Milligan, G. , Alvarez-Curto, E. , Hudson, B. D. , Prihandoko, R. and Tobin, A. B. (2017) FFA4/GPR120: pharmacology and therapeutic opportunities. Trends in Pharmacological Sciences, 38(9), pp. 809-821. (doi: 10.1016/j.tips.2017.06.006) (PMID:28734639) (PMCID:PMC5582618)
Watterson, K. R. et al. (2017) Probe-dependent negative allosteric modulators of the long-chain free fatty acid receptor FFA4. Molecular Pharmacology, 91(6), pp. 630-641. (doi: 10.1124/mol.116.107821) (PMID:28385906) (PMCID:PMC5438128)
Houthuijzen, J. M. et al. (2017) Fatty acid 16:4(n-3) stimulates a GPR120-induced signaling cascade in splenic macrophages to promote chemotherapy resistance. FASEB Journal, 31(5), pp. 2195-2209. (doi: 10.1096/fj.201601248R) (PMID:28183801) (PMCID:PMC5388545)
Hansen, A. H., Sergeev, E. , Pandey, S. K., Hudson, B. D. , Christiansen, E., Milligan, G. and Ulven, T. (2017) Development and characterization of a fluorescent tracer for the free fatty acid receptor 2 (FFA2/GPR43). Journal of Medicinal Chemistry, 60(13), pp. 5638-5645. (doi: 10.1021/acs.jmedchem.7b00338) (PMID:28570808)
Milligan, G. , Shimpukade, B., Ulven, T. and Hudson, B. D. (2017) Complex pharmacology of free fatty acid receptors. Chemical Reviews, 117(1), pp. 67-110. (doi: 10.1021/acs.chemrev.6b00056) (PMID:27299848)
Azevedo, C. M. G. et al. (2016) Non-acidic free fatty acid receptor 4 agonists with antidiabetic activity. Journal of Medicinal Chemistry, 59(19), pp. 8868-8878. (doi: 10.1021/acs.jmedchem.6b00685)
Hansen, S. V.F. et al. (2016) Discovery of a potent free fatty acid 1 receptor agonist with low lipophilicity, low polar surface area and robust in vivo efficacy. Journal of Medicinal Chemistry, 59, pp. 2841-2846. (doi: 10.1021/acs.jmedchem.5b01962)
Grundmann, M., Tikhonova, I. G., Hudson, B. D. , Smith, N. J., Mohr, K., Ulven, T., Milligan, G. , Kenakin, T. and Kostenis, E. (2016) A molecular mechanism for sequential activation of a G Protein-coupled receptor. Cell Chemical Biology, 23(3), pp. 392-403. (doi: 10.1016/j.chembiol.2016.02.014) (PMID:26991104)
Sergeev, E. , Hansen, A. H., Pandey, S. K., MacKenzie, A. E., Hudson, B. D. , Ulven, T. and Milligan, G. (2016) Non-equivalence of key positively charged residues of the free fatty acid 2 receptor in the recognition and function of agonist versus antagonist ligands. Journal of Biological Chemistry, 291, pp. 303-317. (doi: 10.1074/jbc.M115.687939) (PMID:26518871) (PMCID:PMC4697166)
Christiansen, E., Hudson, B. D. , Hansen, A. H., Milligan, G. and Ulven, T. (2016) Development and characterization of a potent free fatty acid receptor 1 (FFA1) fluorescent tracer. Journal of Medicinal Chemistry, 59(10), pp. 4849-4858. (doi: 10.1021/acs.jmedchem.6b00202) (PMID:27074625)
Prihandoko, R., Alvarez-Curto, E. , Hudson, B. D. , Butcher, A. J., Ulven, T., Miller, A. M., Tobin, A. B. and Milligan, G. (2016) Distinct phosphorylation clusters determines the signalling outcome of the free fatty acid receptor FFA4/GPR120. Molecular Pharmacology, 89(5), pp. 505-520. (doi: 10.1124/mol.115.101949) (PMID:26873857)
Milligan, G. , Alvarez-Curto, E. , Watterson, K.R., Ulven, T. and Hudson, B.D. (2015) Characterizing pharmacological ligands to study the long-chain fatty acid receptors GPR40/FFA1 and GPR120/FFA4. British Journal of Pharmacology, 172(13), pp. 3254-3265. (doi: 10.1111/bph.12879) (PMID:25131623)
Christiansen, E. et al. (2015) Activity of dietary fatty acids on FFA1 and FFA4 and characterisation of pinolenic acid as a dual FFA1/FFA4 agonist with potential effect against metabolic diseases. British Journal of Nutrition, 113(11), pp. 1677-1688. (doi: 10.1017/S000711451500118X) (PMID:25916176)
Hudson, B. D. , Christiansen, E., Murdoch, H., Jenkins, L. , Hansen, A. H., Madsen, O., Ulven, T. and Milligan, G. (2014) Complex pharmacology of novel allosteric free fatty acid 3 receptor ligands. Molecular Pharmacology, 86(2), pp. 200-210. (doi: 10.1124/mol.114.093294)
Hudson, B. D. , Shimpukade, B., Milligan, G. and Ulven, T. (2014) The molecular basis of ligand interaction at free fatty acid receptor 4 (FFA4/GPR120). Journal of Biological Chemistry, 289, pp. 20345-20358. (doi: 10.1074/jbc.M114.561449) (PMID:24860101) (PMCID:PMC4106347)
Butcher, A. J., Hudson, B. D. , Shimpukade, B., Alvarez-Curto, E. , Prihandoko, R., Ulven, T., Milligan, G. and Tobin, A. B. (2014) Concomitant action of structural elements and receptor phosphorylation determine arrestin-3 interaction with the free fatty acid receptor FFA4. Journal of Biological Chemistry, 289, pp. 18451-18465. (doi: 10.1074/jbc.M114.568816) (PMID:24817122) (PMCID:PMC4140278)
Fjaere, E. et al. (2014) Indomethacin treatment prevents high fat diet-induced obesity and insulin resistance but not glucose intolerance in C57BL/6J mice. Journal of Biological Chemistry, 289(23), pp. 16032-16045. (doi: 10.1074/jbc.M113.525220)
Milligan, G. , Ulven, T., Murdoch, H. and Hudson, B. D. (2014) G-protein-coupled receptors for free fatty acids: nutritional and therapeutic targets. British Journal of Nutrition, 111(S1), S3-S7. (doi: 10.1017/S0007114513002249)
Mackenzie, A.E. et al. (2014) The antiallergic mast cell stabilizers lodoxamide and bufrolin as the first high and equipotent agonists of human and rat gpr35. Molecular Pharmacology, 85(1), pp. 91-104. (doi: 10.1124/mol.113.089482)
Watterson, K. R., Hudson, B. D. , Ulven, T. and Milligan, G. (2014) Treatment of type 2 diabetes by free fatty acid receptor agonists. Frontiers in Endocrinology, 5, 137. (doi: 10.3389/fendo.2014.00137) (PMID:25221541) (PMCID:PMC4147718)
Hudson, B.D. , Shimpukade, B., Mackenzie, A.E., Butcher, A.J., Pediani, J.D. , Christiansen, E., Heathcote, H., Tobin, A.B., Ulven, T. and Milligan, G. (2013) The pharmacology of TUG-891, a potent and selective agonist of the free fatty acid receptor 4 (FFA4/GPR120), demonstrates both potential opportunity and possible challenges to therapeutic agonism. Molecular Pharmacology, 84(5), pp. 710-725. (doi: 10.1124/mol.113.087783)
Dranse, H.J., Kelly, M.E.M. and Hudson, B.D. (2013) Drugs or diet? - Developing novel therapeutic strategies targeting the free fatty acid family of GPCRs. British Journal of Pharmacology, 170(4), pp. 696-711. (doi: 10.1111/bph.12327)
Hudson, B. D. , Kulp, K. S. and Loots, G. G. (2013) Prostate cancer invasion and metastasis: insights from mining genomic data. Briefings in Functional Genomics, 12(5), pp. 397-410. (doi: 10.1093/bfgp/elt021)
Hudson, B.D. , Murdoch, H. and Milligan, G. (2013) The effects of species ortholog and SNP variation on receptors for free fatty acids. Molecular Endocrinology, 27(8), pp. 1177-1187. (doi: 10.1210/me.2013-1085)
Hudson, B.D. et al. (2013) Defining the molecular basis for the first potent and selective orthosteric agonists of the FFA2 free fatty acid receptor. Journal of Biological Chemistry, 288(24), pp. 17296-17312. (doi: 10.1074/jbc.M113.455337)
Christiansen, E. et al. (2013) Discovery of TUG-770: a highly potent free fatty acid receptor 1 (FFA1/GPR40) agonist for treatment of type 2 diabetes. ACS Medicinal Chemistry Letters, 4(5), pp. 441-445. (doi: 10.1021/ml4000673)
Christiansen, E. et al. (2013) Discovery of a potent and selective free fatty acid receptor 1 agonist with low lipophilicity and high oral bioavailability. Journal of Medicinal Chemistry, 56(3), pp. 982-992. (doi: 10.1021/jm301470a)
Hudson, B. D. , Ulven, T. and Milligan, G. (2013) The therapeutic potential of allosteric ligands for free fatty acid sensitive GPCRs. Current Topics in Medicinal Chemistry, 13(1), pp. 14-25. (doi: 10.2174/1568026611313010004)
Mackenzie, A. E., Neetoo-Isseljee, Z., Southern, C., Jerman, J., McIver, E. G., Hudson, B. D. , Taylor, D. L. and Milligan, G. (2013) Novel and potent GPR35 agonists aid identification of residues important in ligand interaction. FASEB Journal, 27, 655.1.
Hudson, B. , Christiansen, E., Tikhonova, I.G., Grundmann, M., Kostenis, E., Adams, D.R., Ulven, T. and Milligan, G. (2012) Chemically engineering ligand selectivity at the free fatty acid receptor 2 based on pharmacological variation between species orthologs. FASEB Journal, 26(12), pp. 4951-4965. (doi: 10.1096/fj.12-213314)
Hudson, B.D. , Tikhonova, I.G., Pandey, S.K., Ulven, T. and Milligan, G. (2012) Extracellular ionic locks determine variation in constitutive activity and ligand potency between species orthologs of the free fatty acid receptors FFA2 and FFA3. Journal of Biological Chemistry, 287(49), pp. 41195-41209. (doi: 10.1074/jbc.M112.396259)
Christiansen, E. et al. (2012) Free fatty acid receptor 1 (FFA1/GPR40) agonists: mesylpropoxy appendage lowers lipophilicity and improves ADME properties. Journal of Medicinal Chemistry, 55(14), pp. 6624-6628. (doi: 10.1021/jm3002026)
Shimpukade, B., Hudson, B.D. , Hogaard, C.K., Milligan, G. and Ulven, T. (2012) Discovery of a potent and selective GPR120 agonist. Journal of Medicinal Chemistry, 55(9), pp. 4511-4515. (doi: 10.1021/jm300215x)
Ottenheijm, C. A.C., Voermans, N. C., Hudson, B. D. , Irving, T., Stienen, G. J.M., van Engelen, B. G. and Granzier, H. (2012) Titin-based stiffening of muscle fibers in Ehlers-Danlos Syndrome. Journal of Applied Physiology, 112(7), pp. 1157-1165. (doi: 10.1152/japplphysiol.01166.2011) (PMID:22223454)
Hudson, B. D. and Kelly, M. E.M. (2012) Identification of novel competing β2AR phospho extracellular signal regulated kinase 1/2 signaling pathways in human trabecular meshwork cells. Journal of Ocular Pharmacology and Therapeutics, 28(1), pp. 17-25. (doi: 10.1089/jop.2011.0016)
Terhzaz, S. , Cabrero, P. , Robben, J.H., Radford, J.C., Hudson, B.D. , Milligan, G. , Dow, J.A.T. and Davies, S.A. (2012) Mechanism and function of drosophila capa GPCR: a desiccation stress-responsive receptor with functional homology to human neuromedinU receptor. PLoS ONE, 7(1), e29897. (doi: 10.1371/journal.pone.0029897) (PMID:22253819) (PMCID:PMC3256212)
Smith, N.J. et al. (2011) Extracellular loop 2 of the free fatty acid receptor 2 mediates allosterism of a phenylacetamide ago-allosteric modulator. Molecular Pharmacology, 80(1), pp. 163-173. (doi: 10.1124/mol.110.070789)
Schmidt, J. et al. (2011) Selective orthosteric free fatty acid receptor 2 (FFA2) agonists: identification of the structural and chemical requirements for selective activation of FFA2 versus FFA3. Journal of Biological Chemistry, 286(12), pp. 10628-10640. (doi: 10.1074/jbc.M110.210872)
Jenkins, L. , Brea, J., Smith, N.J., Hudson, B.D. , Reilly, G., Bryant, N.J., Castro, M., Loza, M.I. and Milligan, G. (2010) Identification of novel species-selective agonists of the G-protein-coupled receptor GPR35 that promote recruitment of β-arrestin-2 and activate Gα13. Biochemical Journal, 432(3), pp. 451-459. (doi: 10.1042/BJ20101287)
Book Sections
Hudson, B. D. (2016) Using biosensors to study free fatty acid receptor pharmacology and function. In: Milligan, G. and Kimura, I. (eds.) Free Fatty Acid Receptors. Series: Handbook of experimental pharmacology (236). Springer, pp. 79-100. ISBN 9783319506920 (doi: 10.1007/164_2016_58)
Hudson, B.D. , Smith, N.J. and Milligan, G. (2011) Experimental challenges to targeting poorly characterized GPCRs: uncovering the therapeutic potential for free fatty acid receptors. In: Neubig, R.R. (ed.) Pharmacology of G Protein Coupled Receptors. Series: Advances in Pharmacology (62). Elsevier Academic Press: Amsterdam, The Netherlands, pp. 175-218. ISBN 9780123859525 (doi: 10.1016/B978-0-12-385952-5.00006-3)
Grants
Grants and Awards listed are those received whilst working with the University of Glasgow.
- A novel paradigm of intracrine fatty acid receptor signalling at lipid droplets: implications for adipocyte physiology and metabolic disease
Medical Research Council
2024 - 2027
- Hudson AMS Springboard
Academy of Medical Sciences
2019 - 2022
- Defining physiological and pathophysiological roles of the Free Fatty Acid Receptor 2 by analysis of novel transgenic mouse models
Biotechnology and Biological Sciences Research Council (BBSRC)
2018 - 2021
- Identification of novel FFA1 and GPR120 ligands and their use in elucidating the pharmacology, function, and clinical utility of these receptors in the treatment of obesity and diabetes
Canadian Institutes of Health Research
2011 - 2014
Supervision
- Duncan, Elaine
Bioengineering 3D Adipose Organoids for Type 2 Diabetes Drug Discovery - Kenawy, Marwa
Detection and characterisation of constitutive Activity Across the Free Fatty Acid Receptors - Lucianno, Olivia Yi Hai Xin
Defining the intracellular dynamics of succinate receptor signalling in macrophages - Purdie, Euan
Exploiting metabolite GPCR mechanotransduction to find new treatments for metabolic disorders
Research datasets
2021
Scarpa, M., Molloy, C. , Jenkins, L. , Strellis, B., Budgett, R., Hesse, S., Dwomoh, L. , Marsango, S., Tejeda, G. , Rossi, M., Ahmed, Z., Milligan, G. , Hudson, B. , Tobin, A. , Bradley, S. and Heptares, S. (2021) Biased M1 muscarinic receptor mutant mice show accelerated progression of prion neurodegenerative disease. [Data Collection]